⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 1, 2024Diabetologie und Stoffwechsel

A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide 1 receptor agonist therapy

Filip K. Knop Shweta Urva Mallikarjuna Rettiganti Charles Benson William C. Roell Kieren J. Mather Axel Haupt Edward Pratt Martin Füchtenbusch

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

How does LY3537021 (LY) in combination with liraglutide impact the safety and tolerability profile related to gastrointestinal (GI) adverse events?

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Knop et al. (2024) studied this question.

synapsesocial.com/papers/68e71184b6db64358768a99f https://doi.org/10.1055/s-0044-1785380

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 DiabetesBlinded Clinical Trial · 2016 · 45 citations
2Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and PharmacodynamicsOriginal Research · 2015 · 217 citations
3Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesityOriginal Research · 2011 · 126 citations
4745-P: Effects of Liraglutide on GLP-1, GIP, and Glucagon Concentrations in Persons with Type 2 Diabetes with Multiple Daily Insulin Injections during a 24-Week Period2024
5Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopyOriginal Research · 2017 · 126 citations
6Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion proteinOriginal Research · 2010 · 306 citations
7A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetesRCT · 2011 · 120 citations
8Coordinated ASBT and EGFR Mechanisms for Optimized Liraglutide Nanoformulation Absorption in the GI Tract2024 · 15 citations
9Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4)Diabetologie und Stoffwechsel · 2024
10Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2Diabetologie und Stoffwechsel · 2024

More from Diabetologie und Stoffwechsel

More from University of Copenhagen

More from Eli Lilly (United States)